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Summary
 
This study shows that induction of tumor-specific CD4
 
1
 
 T cells by vaccination with a specific
viral T helper epitope, contained within a synthetic peptide, results in protective immunity
against major histocompatibility complex (MHC) class II negative, virus-induced tumor cells.
Protection was also induced against sarcoma induction by acutely transforming retrovirus. In
contrast, no protective immunity was induced by vaccination with an unrelated T helper
epitope. By cytokine pattern analysis, the induced CD4
 
1
 
 T cells were of the T helper cell 1
type. The peptide-specific CD4
 
1
 
 T cells did not directly recognize the tumor cells, indicating
involvement of cross-priming by tumor-associated antigen-presenting cells. The main effector
cells responsible for tumor eradication were identified as CD8
 
1
 
 cytotoxic T cells that were
found to recognize a recently described immunodominant viral gag-encoded cytotoxic T lym-
phocyte (CTL) epitope, which is unrelated to the viral env-encoded T helper peptide se-
quence. Simultaneous vaccination with the tumor-specific T helper and CTL epitopes resulted
in strong synergistic protection. These results indicate the crucial role of T helper cells for opti-
mal induction of protective immunity against MHC class II negative tumor cells. Protection is
dependent on tumor-specific CTLs in this model system and requires cross-priming of tumor
antigens by specialized antigen-presenting cells. Thus, tumor-specific T helper epitopes have to
be included in the design of epitope-based vaccines.
 
A
 
dequate T helper cell activation is essential in the initi-
ation of an immune reaction. The inability to control
tumor outgrowth can be due to inadequate T helper re-
sponses underlying poor tumor-specific immunity. In the
cellular immune response, specialized APCs process protein
and present antigenic peptide fragments in MHC class II
molecules to CD4
 
1
 
 T helper lymphocytes. These provide
“help” to effector cells via the production of cytokines. Al-
though tumor cells can directly present endogenously pro-
cessed antigenic peptide in surface MHC class I molecules
to CD8
 
1
 
 CTL precursors, initiation of tumor-specific CTL
responses is likely to involve indirect presentation of tumor
antigens by specialized APCs.
Evidence for a role of T helper cell–mediated immunity
comes from studies with genetically modified tumor cells.
CD4
 
1
 
 cells can be directly activated by transfection of
MHC class II 
 
a
 
 and 
 
b
 
 chain genes in mouse tumor cells
(1–4). These cells become immunogenic, lose their tumor-
igenicity, and even induce protection against wild-type
MHC class II negative tumors, indicating that direct MHC
class II presentation of tumor expressed antigens can induce
efficient anti–tumor responses.
A central role of CD4
 
1
 
 T cells emerged from studies of
immunity against FMR (Friend, Moloney, Rauscher)
 
1
 
 mu-
rine leukemia virus (MuLV) type tumors by Greenberg (5).
Transfer of purified polyclonal T cells from FBL (Friend
MuLV-induced erythroleukemia cell line) vaccinated mice
in naive animals can protect these mice against subsequent
tumor challenge. Both purified CD4
 
1
 
 and CD8
 
1
 
 T cells
transfer protection to FBL tumors (6). FBL cells do not ex-
press MHC class II molecules, but CD4
 
1
 
 T cells can pro-
tect mice even in the absence of CD8
 
1
 
 T cells. In this case,
macrophages seem to play an important effector role.
CD8
 
1
 
 T cells can only be effective if CD4
 
1
 
 T cells are
present or if exogenous IL-2 is administered. Neither B
cells nor NK cells seem to exert a significant role in the
FBL sytem. These data suggest involvement of APCs, pre-
senting tumor antigens, and a crucial regulatory role of
Ths, which was strongly supported by experiments per-
 
1
 
Abbreviations used in this paper:
 
 FMR, Friend, Moloney, Rauscher; gag-L,
gag-leader; gp, glycoprotein; MoMSV, Moloney murine sarcoma and
leukemia virus complex; MuLV, murine leukemia virus; n.s., not significant.
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formed in Friend MuLV env-transgenic mice (7). These
mice were rendered tolerant for env-specific Th responses
and it was not possible to protect these mice against FBL
tumors by vaccination.
Immune responsiveness to MuLV is classically regulated
by the genes of the H-2 (MHC) complex (8). In particular,
the H-2
 
b
 
 haplotype confers resistance, and studies using H-2
recombinant and H-2 mutant mouse strains have mapped
the protective effects to the class II I-A
 
b
 
 locus (9, 10). This
MHC class II association indicates an important role of T
helper cells influencing both CTL activity as well as class
switching of antiviral antibodies from IgM to IgG. The
H-2 I-A
 
b
 
 phenotype protects against early lymphomagene-
sis. The identification of two Friend MuLV env-derived
epitopes, presented by MHC class II, I-A
 
b
 
 and I-E
 
b/d
 
, re-
spectively, indicated that tumor-directed T helper immu-
nity is virus specific (11). The few lymphomas that arise in
H-2
 
b
 
 mice have abrogated viral antigen or (more rarely)
MHC class I expression (12), indicating that CTLs also play
a crucial role. CTLs have been proven to recognize viral
antigens, both gag and env proteins encode CTL epitopes
(13). We have identified a K
 
b
 
-presented, env-derived
Moloney and Rauscher CTL epitope that is subdominant
in C57BL/6 mice making use of the D
 
b
 
 mutant BM13
mouse strain (14). The D
 
b
 
-presented gag-leader (gag-L) de-
rived immunodominant CTL epitope for the FMR type of
MuLV has been identified only recently (15).
Vaccination with a synthetic peptide comprising a rele-
vant T cell epitope is a powerful method to induce highly
specific T cells. Protective vaccination using CTL peptide
epitopes has been achieved in pathogenic viral models (16,
17) and tumor models (18–20). Peptide vaccination in IFA
led to measurable specific CTL induction and protective
immunity against virulent virus or tumor cells. Importantly,
peptide vaccination can also be applied succesfully for ther-
apy of established tumors by presenting the peptide in IFA,
on RMA-S cells, or on activated dendritic cells (21, 22).
We now report the induction of tumor-protective im-
munity by a single vaccination with a tumor-specific
MuLV env-encoded T helper peptide. Strong protection
can be achieved against highly aggressive tumor cells that
lack MHC class II expression. This indicates the require-
ment of cross-priming of tumor antigens by local APCs.
We show that CD8
 
1
 
 T cells, recognizing the gag-L–encoded
CTL epitope, are crucial effector cells that are efficiently
activated with help from peptide-primed tumor-specific
CD4
 
1
 
 T cells. Vaccination with a mixture of the T helper
peptide and the immunodominant CTL epitope resulted in
synergistic, long-term tumor protection.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6 Kh, H-2
 
b
 
) mice were bred under specific
pathogen-free conditions at TNO-PG (Leiden, The Netherlands).
 
Cell Lines, Viruses, and Antibodies.
 
771 is an MCF1233-induced
B cell lymphoma cell line from a C57BL/10 mouse neonatally
inoculated with MCF1233 MuLV as described (23). RMA is a
mutagenized derivative of RBL-5, a Rauscher MuLV-induced T
lymphoma cell line of C57BL/6 origin (24). EL-4 is a chemically in-
duced (non-MuLV–induced) T cell lymphoma of C57BL/6 ori-
gin. HeLaD
 
b
 
 is a stable transfectant of the human cervix carci-
noma cell line HeLa, expressing the murine MHC class I mole-
cule D
 
b
 
.
Moloney murine sarcoma and leukemia virus complex
(MoMSV) was prepared and injected in the left thigh intramuscu-
larly for sarcoma induction as described (25). Moloney Abelson
virus was used for infection of B6 LPS blasts as described (25).
Monoclonal antibodies used for immunofluorescence staining
and FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA) analysis
were: anti-K
 
b
 
 (B8.24.3), anti-D
 
b
 
 (28.14.8S), anti–I-A
 
b
 
 (17.227
and Y3P), anti-CD4 (H129.19), anti-CD8 (53.6.7), and anti-
CD3 (500A2).
Monoclonal antibodies used for in vivo depletion of the CD4
 
1
 
and CD8
 
1
 
 T cell subsets were GK1.5 and 2.43, respectively. Pu-
rified antibodies were administered by intraperitoneal injection of
100 
 
m
 
g of antibody in 0.2 ml PBS, in schedules that are specified
in the figure legends.
 
Peptides.
 
Peptides were synthesized on multiple peptide syn-
thesizer (442; ABIMED, Langenfeld, Germany) as previously de-
scribed (26). Peptides were analyzed for purity by reverse phase
HPLC and lyophilized. The T helper epitope peptide env-H19
EPLTSLTPRCNTAWNRLKL (11) (and its length variants) and
the env-derived CTL epitope peptide env-K
 
b
 
8 SSWDFITV (14)
were dissolved in PBS. The dominant gag-L–derived CTL
epitope peptide was used as a 10-mer (gag-L–D
 
b
 
10) or a 9-mer
(gag-L–D
 
b
 
9) (L)CCLCLTVFL (15) was dissolved in DMSO (20
 
m
 
l/mg peptide) and diluted in PBS. The Sendai virus nucleoprotein
CTL epitope SV9 (FAPGNYPAL) was used as a control K
 
b
 
-binding
peptide (16). The ovalbumin T helper peptide OvaH (ISQAVHAA-
HAEINEAGR) (27) was used as a control I-A
 
b
 
–binding peptide.
This peptide induces strong CD4 responses in C57BL/6 mice.
Stock solutions of 5 mg/ml were stored at 
 
2
 
80
 
8
 
C.
 
Peptide Vaccination and Tumor Challenge.
 
C57BL/6 mice, aged
7–10 wk, were vaccinated with a single dose of synthetic peptide
(0.1–100 
 
m
 
g/mouse) in 50% (vol/vol) emulsion with IFA admin-
istered in a 0.2-ml depot subcutaneously. Control groups were
similarly injected with a 50% (vol/vol) emulsion of PBS and IFA.
After 14 d, the mice were challenged with 10
 
3
 
 RMA tumor cells
in 0.2 ml PBS, 0.1% (wt/vol) BSA, intraperitoneally. Weights of
the mice were monitored every other day. Mice were killed if
their weight increased for 
 
.
 
25%. Statistical analysis on the sur-
vival data was performed using the log rank test. Significance was
defined as probability values below 0.05.
 
T Cell Culture.
 
CD4
 
1
 
 T cells were obtained from T helper
peptide immunized mice by culturing spleen cells (3 
 
3
 
 10
 
6
 
 cells/
well of 24-well plates) in the presence of 10 
 
m
 
g/ml T helper pep-
tide in complete medium in the absence of exogenous IL-2. Bulk
cultures after 1 wk were mainly (70–80%) CD4
 
1
 
 as determined
by FACScan
 
Ò
 
 analysis. The bulk culture was restimulated using
irradiated B6 spleen cells in the presence of 10 
 
m
 
g/ml T helper
peptide without IL-2. Clones were isolated by limiting dilution
and tested for peptide specificity.
T helper clone 3A12 (CD4
 
1
 
) and CTL clone 2H9 (CD8
 
1
 
)
was isolated from a bulk spleen cell culture of tumor-protected
mice immunized with 11-mer MuLV T helper peptide (H11.1)
that were challenged with 10
 
3
 
 live RMA tumor cells. Spleen cells
were restimulated with mitomycin-C (50 
 
m
 
g/ml for 1 h at 37
 
8
 
C)
-treated and irradiated (25 Gy) RMA tumor cells. After 1 wk,
bulk cultures were seeded under limiting dilution conditions and
clones were randomly isolated and tested for specific proliferative
capacity and cytotoxicity against RMA tumor cells. 
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All cells were cultured in Iscove’s modified Dulbecco’s me-
dium (GIBCO Biocult, Glasgow, UK) supplemented with 5%
FCS (tumor cells) or 10% FCS (CTL), penicillin, (100 IU/ml)
and 20 
 
m
 
M 2-mercaptoethanol. T cell clones were cultured in
the presence of 20 IU/ml human recombinant IL-2.
 
Proliferation Assays.
 
Proliferation assays were carried out in
96-well U-bottomed plates using CD4
 
1
 
 T cells as responder cells
at 4 
 
3
 
 10
 
4
 
, 2 
 
3
 
 10
 
4
 
, 10
 
4
 
, and 5 
 
3
 
 10
 
3
 
 cells/well. Several stimula-
tor cells were tested: irradiated (25 Gy) spleen cells (10
 
5
 
 cells/well),
with or without T helper peptide (5–10 
 
m
 
g/ml), with or without
tumor cells (mitomycin-C–treated and irradiated RMA cells; 2 
 
3
 
10
 
4
 
 cells/well). All assays were performed in the absence of exoge-
nous IL-2. After 3 d, the cultures were pulsed with [
 
3
 
H]thymi-
dine (New England Nuclear, Boston, MA; 0.5 
 
m
 
Ci/well) for 5 h.
The results are expressed as mean cpm of triplicate cultures. Stan-
dard deviations were 
 
,
 
10% of the mean.
 
Cytotoxicity Assays.
 
CTL assays were performed as described
(23). In short, 2 
 
3
 
 10
 
3
 
 Na
 
2
51
 
CrO
 
4
 
-labeled target cells were incu-
bated with effector cells for 5–6 h at 37
 
8
 
C. The culture super-
natant was harvested and counted for released radioactivity. The
percentage of specific 
 
51
 
Cr-release was calculated as a ratio of 100 
 
3
 
(cpm experimental release 
 
2
 
 cpm spontaneous release)/(cpm
maximal release [1% Triton X-100] 
 
2
 
 cpm spontaneous release).
All assays were carried out in triplicate. For target cell sensitiza-
tion, 
 
51
 
Cr-labeled target cells were incubated with peptide 1 h
before addition of the CTLs. Peptides remained present during
the assay.
 
Cytokine Assays.
 
Bioactive IL-2 production was determined
using the IL-2–dependent cell line CTLL2. 50 
 
m
 
l supernatant of
specifically stimulated CD4
 
1
 
 T cell clones (3-d stimulation with
irradiated [25 Gy] 771 [I-A
 
b
 
1
 
] cells with and without env-H19
peptide) was incubated with 5 
 
3
 
 10
 
3
 
 CTLL2 cells in a total vol-
ume of 100 
 
m
 
l. As a standard, human recombinant IL-2 was used.
After 24 h, the wells were pulsed with [
 
3
 
H]thymidine (New En-
gland Nuclear; 0.5 
 
m
 
Ci/well) for 5 h. All determinations were
performed in triplicate and standard deviations were 
 
,
 
10% of the
mean.
The presence of cytokine transcripts of IFN-
 
g
 
, IL-2, IL-3, IL-4,
IL-5, and IL-6 were tested by reverse transcriptase PCR using cy-
tokine-specific primer sets as described (28). CD4
 
1
 
 T cell clones
were specifically stimulated with env-H19 peptide-loaded 771
cells for 2 and 16 h and total RNA and cDNA was prepared as
described (29). Controls were CD4
 
1
 
 T cells incubated with 771
cells without peptide, CD4
 
1
 
 T cell alone, and 771 cells with pep-
tide without CD4
 
1
 
 T cells. Control reactions without reverse
transcriptase were always negative for any primer set.
 
RMA-S MHC Class I Peptide-binding Assay.
 
The RMA-S as-
say was performed as described previously (18). In short, RMA-S
cells were cultured for 36 h at 26
 
8
 
C and were added to serial dilu-
tions of peptide in serum-free medium. After a 4-h incubation at
37
 
8
 
C, cells were washed and incubated with the D
 
b
 
-specific mAb
28.14.8S for 30 min on ice. After washing, the cells were incu-
bated with FITC-conjugated goat anti–mouse IgG F(ab
 
9
 
)2 frag-
ments for 30 min on ice and immunofluorescence was analyzed
using a FACScan
 
Ò
 
 flow cytometer.
 
Results
 
Peptide Vaccination with T Helper Epitope Peptide Leads to
Protective Immunity.
 
MuLV-encoded epitope peptides were
tested for their capacity to induce tumor-protective im-
mune responses in vivo. Synthetic peptide diluted in saline
and emulsified in IFA was injected subcutaneously. The
subdominant 8-mer CTL epitope env-Kb (SSWDFITV;
reference 14) and the T helper 19-mer peptide env-H19
(EPLTSLTPRCNTAWNRLKL), originally described as a
Friend MuLV T helper epitope (11) sharing identical se-
quences with Moloney and Rauscher MuLV but not with
AKV/MCF type MuLV, were used to vaccinate immuno-
competent C57BL/6 mice. After 14 d, the mice were chal-
lenged intraperitoneally with the Rauscher MuLV-induced
tumor cell line RMA. RMA is an aggressively growing T
cell lymphoma, lethal for mice within 4 wk when as few as
1000 cells are administered. RMA expresses MHC class I
Kb and Db but is negative for MHC class II expression even
after IFN-g treatment, as monitored by staining with spe-
cific antibodies and Northern blotting analysis (data not
shown). RMA cells isolated from the peritoneal cavity 3
wk after inoculation in C57BL/6 mice were tested for
MHC expression and found to have retained their I-Ab
negative phenotype in vivo (data not shown). Fig. 1 shows
the weight increase of individual mice in time, reflecting
ascites tumor growth. The subdominant CTL epitope env-
Kb8, despite being expressed by RMA cells (14), did not
induce a protective response (Fig. 1 B). In contrast, vacci-
nation with the env-H19 T helper peptide (Fig. 1 C) led to
inhibition of RMA tumor growth in a significant number
of mice. Combined vaccination with the T helper and the
subdominant env-Kb8 CTL epitopes (Fig. 1 D) did not sig-
nificantly increase survival beyond that seen with the T
helper peptide alone, within the first 40 d after tumor chal-
lenge. Fig. 2 shows 100-d survival of mice vaccinated with
MuLV CTL and T helper peptides compared with an irrel-
evant ovalbumin T helper peptide (OvaH; reference 27).
Vaccination with the OvaH peptide alone or in combina-
tion with the env-Kb8 CTL epitope did not induce detect-
able protection, whereas the MuLV T helper peptide in-
duced long-term protection in 40% of the mice (Fig. 2 A).
The combination vaccine (env-Kb8 and env-H19 mixture)
induced long-term protection of 70% of the animals. This
difference was not found to be statistically significant (P 5
0.28). The nonrelated CTL and T helper epitopes Sendai virus
SV-Kb9 and OvaH, respectively, did not induce measurable
protective immunity. The recently described gag-L–derived,
Db-presented dominant CTL epitope (L)CCLCLTVFL
(15) was tested in a similar way (Fig. 2 B). The gag-L–Db
peptide is able to induce protection in 20–40% of the mice
either as a 9 or 10 mer. The mixture of the env T helper
peptide and the gag-L CTL epitope peptide resulted in
very efficient protection leading to long-term survival of
90% of the mice. The requirement for induction of tumor-
specific T helper cells is shown in Fig. 2 C. Vaccination
with a mixture of OvaH with the gag-L–Db9 peptide re-
sulted in significantly less efficient protection than the com-
bination vaccine of MuLV env-derived T helper peptide
with the gag-L peptide. These results show that tumor-spe-
cific T helper peptide vaccination as such can induce effi-
cient protective immunity against MHC class II negative696 T Helper Cell Defense against MHC Class II Negative Tumors
tumor cells. This protective effect can be further enhanced
by vaccination of T helper peptide in combination with
CTL epitope-bearing peptides.
In addition, we tested the ability of the helper peptide to
protect mice against virus-induced tumorigenesis next to
the in vitro–established tumor cell line RMA. The effect of
peptide vaccination on sarcoma induction by MoMSV was
determined by measuring thigh thickness. This retrovirus
complex characteristically induces acute transformation of
muscle cells and rapid tumor growth (within 2 wk), and an
efficient T cell response can control tumor growth (nude
mice die because of progressive tumor growth, data not
shown) as evidenced by tumor regression within a month
(Fig. 3 A). Vaccination with the T helper peptide signifi-
cantly reduced tumor induction (five out of seven mice re-
Figure 1. T helper peptide vaccination protects mice against intraperi-
toneal tumor induction. C57BL/6 mice were vaccinated with synthetic
peptide (100 mg/mouse) in a 50% PBS/IFA (vol/vol) emulsion subcuta-
neously at day 214 and challenged with 1,000 RMA cells intraperito-
neally at day zero. The weights of the individual mice were monitored
every other day and the percent weight increase is depicted. Each line is
an individual mouse. (A) Six mice were injected with an emulsion of IFA
with PBS without peptide as a negative control. (B) Six mice were vacci-
nated with the subdominant Kb-presented MuLV env–gp70 CTL epitope
peptide env-Kb8 (SSWDFITV). (C) Seven mice were vaccinated with the
I-Ab–presented 19-mer MuLV env–gp70 T helper epitope peptide env-
H19 (EPLTSLTPRCNTAWNRLKL). (D) 10 mice were vaccinated
with a mixture of env-Kb8 and env-H19 (both 100 mg) in a single vaccine
depot.
Figure 2. (A) Tumor-specific T helper peptide vaccination increases
long-term survival of mice challenged with tumor cells. C57BL/6 mice
were vaccinated with synthetic peptides as described in the legend of Fig.
1. All groups received IFA (50% vol/vol) with or without 100 mg peptide
subcutaneously. The percentage of surviving mice is depicted. Mice were
killed when the weight increase was .25%. PBS, nonimmunized control
(n 5 6); SV-Kb9, nonrelated Sendai virus nucleoprotein Kb-presented CTL
epitope (FAPGNYPAL; n 5 6); env-Kb8, MuLV env–gp70 subdominant
CTL epitope (n 5 7); env-H19, 19-mer MuLV env–gp70 T helper
epitope (n 5 7); env-Kb8 1 env-H19, mixture vaccine of MuLV CTLs and T
helper epitopes (n 5 10); OvaH, nonrelated ovalbumin I-Ab–presented T
helper epitope (ISQAVHAAHAEINEAGR; n 5 6); env-Kb8 1 OvaH,
mixture of MuLV subdominant CTL epitope and ovalbumin T helper
epitope. Significance of differences (log rank test): PBS versus env-H19:
P 5 0.04; PBS versus env-Kb8 1 env-H19: P 5 0.0015; env-H19 versus
env-Kb8 1 env-H19: P 5 0.28 (not significant; n.s.). (B) Combination of
T helper peptide and the immunodominant gag-L CTL epitope induces
highly efficient tumor protection. C57BL/6 mice were immunized with
synthetic peptides in IFA subcutaneously (50 mg/mouse) at day 214 and
challenged with 103 RMA tumor cells intraperitoneally. Long-term sur-
vival was monitored. gag-L-Db10, gag-L CTL epitope (LCCLCLTVFL);
env-H13.3, env-gp70 T helper peptide (SLTPRCNTAWNRL). All groups:
n 5 10. Significance of differences (log rank test): PBS versus gag-L-Db10: P
5 0.0078; PBS versus env-H13.3: P 5 0.0078; PBS versus gag-L-Db10 1
env-H13.3: P 5 0.0001; gag-L-Db10 versus gag-L-Db10 1 env-H13.3: P
5 0.0108; env-H13.3 versus gag-L-Db10 1 env-H13.3: P 5 0.025. (C)
Efficient protection by dominant CTL epitope requires specific help.
Similar experiment using the 9-mer dominant CTL epitope gag-L–Db9 in
combination with either the MuLV T helper peptide env-H13.3 or the
nonrelated OvaH T helper peptide. All groups: n 5 8. Significance of dif-
ferences (log rank test): gag-L-Db9 versus gag-L-Db9 1 OvaH: P 5 0.169
(n.s.); gag-L-Db9 versus gag-L-Db9 1 env-H13.3: P 5 0.003; gag-L-Db9
1 OvaH versus gag-L-Db9 1 env-H13.3: P 5 0.04; PBS versus gag-
L-Db9 1 env-H13.3: P 5 0.0004.697 Ossendorp et al.
mained tumor-free) as well as tumor size (Fig. 3 B). Here
we have used a 13-mer peptide and only 10 mg/mouse.
This indicates that preimmunized MuLV-specific T helper
cells can also control tumor growth by acutely transforming
retroviruses.
Optimization of Peptide Length and Dose. The MuLV T
helper peptide was originally identified as a 20 mer using
Friend MuLV-specific CD41 T cells, and the optimally
recognized sequence was found to be a 13-mer LTSLT-
PRCNTAWN (30). We investigated the minimal peptide
length that was still able to protect mice against the Raus-
cher MuLV-induced lymphoma RMA. Table 1 shows the
comparison of several length variants of the T helper pep-
tide on their tumor-protective capacity in C57BL/6 mice.
These data show that the minimal peptide that still protects
is the 10-mer LTPRCNTAWN and longer peptides with
additional flanking residues can also protect. Titration of
four of these peptides (Table 2) shows that longer peptides
can still protect at 1 mg/mouse, whereas the 10-mer core
peptide can only protect with doses as low as 10 mg/
mouse, indicating that longer peptides are more efficient in
triggering the proper T helper cell population. The 13-mer
peptide H13.3 (SLTPRCNTAWNRL) was selected for
further studies.
Mechanism of T Helper Peptide-induced Tumor Protection.
These results show that a single vaccination with a syn-
thetic peptide, which was reported as a T helper epitope,
leads to substantial tumor protection. We investigated the
contribution of CD41 and CD81 T cells in this model
both in vivo and in vitro. C57BL/6 mice were treated with
antibodies against CD4 and CD8. Antibody treatment re-
sulted in depletion of .95% of the respective T cell subsets
as monitored by FACScanÒ analysis of spleen cells (data not
shown). Fig. 4 A shows the dramatic effect of CD4 deple-
tion during the peptide immunization phase before tumor
challenge. Anti-CD4 treatment almost completely abro-
gates the protective effect of peptide vaccination, indicating
the necessity of the presence of CD41 T cells during the
induction period. In addition, mice were treated with anti-
CD4 and anti-CD8 during the effector period, i.e., just af-
ter RMA tumor challenge. Fig. 4 B shows that depletion of
either CD4 or CD8 positive cells completely abrogates the
survival of mice that were preimmunized with the T helper
peptide. This indicates that both CD41 and CD81 T cells
are essential in the effector phase, suggesting that upon tu-
mor challenge, tumor-specific T helper cells are required
for prompt activation of CD8 positive effector cells.
The T cell response to the synthetic peptide was investi-
gated by in vitro analysis of T cells obtained from peptide-
vaccinated mice. Spleen cells from mice that were vacci-
nated with env-H19 synthetic peptide were restimulated
after 14 d with env-H19 peptide-loaded spleen cells in
Table 1. In Vivo Tumor-protective Capacity of Length Variants of 
MuLV env–gp70 T Helper Peptide
Peptide Sequence
Surviving mice
at day 40
H19 EPLTSLTPRCNTAWNRLKL 5/7
H17 LTSLTPRCNTAWNRLKL 5/7
H15.2 SLTPRCNTAWNRLKL 3/7
H13.2 TPRCNTAWNRLKL 2/7
H10.2 CNTAWNRLKL 0/7
H9.2 NTAWNRLKL 0/7
H15.1 LTSLTPRCNTAWNRL 5/7
H13.3 SLTPRCNTAWNRL 6/7
H11.2 TPRCNTAWNRL 1/7
H13.1 LTSLTPRCNTAWN 4/7
H11.1 SLTPRCNTAWN 5/7
H10.1 LTPRCNTAWN 4/7
H9.1 TPRCNTAWN 1/7
Mice were injected with a single dose of 100 mg peptide in IFA subcu-
taneously 14 d before challenge with 1,000 RMA tumor cells intraperi-
toneally.
Table 2. Optimization of T Helper Peptide Dose for In Vivo 
Tumor Protection
Peptide
Peptide dose
100 mg 10 mg1   m g 0.1 mg
H19 3/6 4/6 5/6 0/6
H13.3 6/6 5/6 4/6 1/6
H10.1 5/6 4/6 1/6 0/6
H9.1 n.t. 1/6 0/6 0/4
Peptide titration of four length variants of MuLV env–gp70 T helper
peptide in vivo. Peptides were administered subcutaneously as a single
dose in IFA. Data represent the number of surviving mice at day 40/
group size. n.t., not tested.
Figure 3. T helper peptide
vaccination protects mice
against retrovirus-induced sar-
coma. C57BL/6 mice were vac-
cinated at day 214 with (A)
PBS-IFA subcutaneously (n 5 7)
and (B) 13-mer MuLV T helper
peptide  H13.3 (SLTPRCN-
TAWNRL), 10 mg/mouse in
IFA subcutaneously (n 5 7). At
day zero mice were injected in
the left thigh muscle with 103 fo-
cus-forming units of MoMSV.
Mice were monitored for tumor
size using a caliper measuring two
perpendicular diameters. Each
line represents one individual
mouse.698 T Helper Cell Defense against MHC Class II Negative Tumors
vitro. Massive outgrowth of CD4 positive cells was ob-
served and several clones obtained after limiting dilution
were tested for specific proliferation and cytokine produc-
tion. We were not able to isolate peptide-specific CD81 T
cells from H19 peptide-immunized mice. The CD41 T
cell clones specifically proliferated on H19 peptide and
shorter peptide length variants in an I-Ab–restricted fashion
(as evidenced by a stimulator cell panel study, data not
shown). Most of the clones (7/10) were also able to recog-
nize 15-mer peptides but not shorter variants, and 3/10
clones were also able to recognize shorter peptides, 13- and
11-mer peptides (not shown). No specific proliferation nor
cytotoxicity of these clones directly to RMA cells, with or
without IFN-g treatment, could be observed that was ex-
pected as the cells lack MHC class II (data not shown). Five
of these clones were tested for peptide-specific cytokine
production profile. All clones produced IL-2 IFN-g, but
not IL-4, IL-3, IL-5, and IL-6 (data not shown), indicating
a Th1 type of T helper response.
In addition, we isolated tumor-specific T cell cultures
from mice that were protected from tumor challenge.
Spleen cells from env-H11.1 peptide-vaccinated mice that
survived RMA tumor challenge after 6 wk were restimu-
lated with RMA cells in vitro. From these T cell cultures
we were able to isolate both CD41 and CD81 T cell
clones. Fig. 5 A shows the peptide and tumor specificity of
CD41 clone 3A12. Although it is not able to recognize the
MHC class II negative RMA cells directly, it specifically
proliferates to the combination of RMA cells with APCs
present in autologous spleen cells, indicating specific recog-
nition of processed RMA-derived antigen. The peptide
fine specificity of clone 3A12 is shown in Fig. 5 B. The
recognition of shorter length variants of the peptide is in
agreement with the observed protective ability of the
Figure 4. Both CD41 and CD81 T cells are involved in the protective
mechanism. C57BL/6 mice were treated with anti-CD4 (GK1.5) and
anti-CD8 (2.43) monoclonal antibodies leading to selective depletion
(.95%) of these T cell subsets. (A) Mice were vaccinated with 100 mg of
H19 in IFA subcutaneously (day 214) and treated five times with 100 mg
GK1.5 monoclonal antibody in 200 ml PBS intraperitoneally during the
vaccination period (days 214, 213, 210, 27, and 24) or as a control
with PBS. At day 0, 103 RMA cells were injected intraperitoneally. Sig-
nificance of differences (log rank test): PBS versus env-H19: P 5 0.0002;
env-H19 1 anti-CD4 versus env-H19: P 5 0.0009; PBS versus env-H19
1 anti-CD4: P 5 0.577 (n.s.). (B) Mice were vaccinated with 10 mg T
helper peptide H13.3 in IFA subcutaneously at day 214 and 103 RMA
cells were injected intraperitoneally at day 0. Antibody treatment (three
times with 100 mg of GK1.5 or 2.43 intraperitoneally) was done during
the effector phase (days 0, 3, and 7). Significance of differences (log rank
test): PBS versus env-H13.3: P 5 0.0027; env-H13.3/anti-CD4 versus
env-H13.3: P 5 0.0013; env-H13.3/anti-CD8 versus env-H13.3: P 5
0.0068.
Figure 5. MuLV-specific CD41
T cells can be isolated from T
helper peptide-immunized mice.
CD41 T cell clones were iso-
lated from T helper peptide-
immunized and RMA-challenged
mice and tested in a 3-d prolifer-
ation assay. Values represent means
of triplicate measurements. (A)
CD41 clone 3A12 was isolated
from a spleen of a protected
mouse, 2 mo after tumor chal-
lenge, that was previously im-
munized with the 11-mer T
helper H11.1 peptide. Spleen
cells were in vitro restimulated
with mitomycin-treated and irra-
diated RMA tumor cells and
CD41 T cell clones were isolated
by limiting dilution. Shaded bars
from black to gray: 4 3 104, 2 3
104, 104, and 5 3 103 cells/well,
respectively. env-H19 peptide
was used at 10 mg/ml. SC, irra-
diated spleen cells (105/well).
RMA cells were mitomycin
treated, irradiated, and used at 2
3 104 cells/well with or without
irradiated spleen cells. 771 is a B
cell lymphoma cell line isolated
from a tumor induced by the
AKV type MCF1233 MuLV
that lacks the T helper epitope
sequence in env (2 3 104 irradi-
ated cells/well). (B) Peptide fine specificity of CD41 clone 3A12. Pep-
tides were used at 5 mg/ml. Shaded bars from dark to light gray: 2 3 104,
104, and 5 3 103 cells/well, respectively. (C) Moloney MuLV specificity
of clone 3A12. LPS B cell blasts were induced using C57BL/6 spleen cells
in the presence or absence of Moloney MuLV (MoLV-LPS). After 3 d, the
LPS blasts were isolated, irradiated, and used as stimulator cells (LPS, 105
cells/well) for clone 3A12 in the presence or absence of H19 peptide (10
mg/ml).699 Ossendorp et al.
shorter peptides (Table 1). Fig. 5 C shows the specific pro-
liferative response of CD41 clone 3A12 to endogenously
processed viral antigen using Moloney MuLV-infected LPS
blasts.
From the same T cell bulks we were able to isolate
RMA-specific CD81 T cell clones. These clones were cy-
totoxic for RMA cells and Db-restricted. Representative
clone 2H9 is shown in Figure 6 A and was found to be spe-
cific for the recently identified common FMR immu-
nodominant CTL epitope that is present in the leader se-
quence of gag (15), but not for another upstream gag-L
epitope (31; Fig. 6 B). No reactivity was found with the T
helper peptide to which the mice were vaccinated, not
even with 9- and 10-mer peptides with potential Db-bind-
ing characteristics (Fig. 6 B). These peptides have undetect-
able MHC class I–binding affinity as tested with the RMA-S
peptide-binding assay (data not shown). This indicates that
no direct CTL priming occurs after vaccination with the T
helper peptide vaccine. Tumor-specific T helper cells are
specifically activated by the peptide that will regulate, de-
pending on cross-priming of tumor antigens, efficient gen-
eration of tumor-specific CTLs. Vaccination of mice with a
combination of the T helper peptide and the dominant
CTL epitope resulted in very efficient protection (Fig. 2
B). These data indicate that specific CTLs are the main ef-
fector cells that require tumor-specific T cell help for effi-
cient antitumor immunity in this system.
Discussion
In this study, we show that a single vaccination with a
synthetic peptide comprising a retrovirus-encoded MHC
class II–presented T helper epitope can induce tumor-pro-
tective immunity against MHC class II negative tumor
cells. This finding underlines a crucial regulatory function
of CD41 T cells in recruiting tumor-directed effector cells
and the necessity of MHC class II–mediated antigen pre-
sentation by, most likely, specialized APCs. In this model,
CTLs appear to be the effector cells that eradicate the tu-
mor cells in vivo since CD8 depletion during the effector
phase resulted in abolition of protection, and peptide vacci-
nation with the relevant CTL epitope led to measurable
protective responses. In a related study we have investi-
gated the protective capacity of three CTL epitopes in rela-
tion to their respective CTL precursor frequencies in
C57BL/6 mice (Van Hall, T., N. van de Rhee, E.
Mengedé, R. Offringa, C.J.M. Melief, and F. Ossendorp,
manuscript submitted for publication). This study indicated
that the immunodominance of the CTL epitope is related
to its protective capacity and is in line with the current
findings.
MuLV env-gp70 T helper peptide vaccination resulted
in long-term protection of 40–50% of the mice and a delay
in tumor growth in 80–90% of the animals in contrast to ir-
relevant ovalbumin T helper peptide vaccination. Al-
though protection is not complete, this indicates a signifi-
cant specific immune response since RMA is an extremely
aggressive tumor cell line in immunocompetent animals.
Strikingly, a combination vaccine containing the immu-
nodominant MuLV gag-L CTL epitope and the T helper
peptide induces highly protective responses leading to
long-term survival of 90% of the mice. Vaccination with
the immunodominant CTL epitope by itself also induces
protection, but is generally far less effective (z30% of the
mice survive). Some bystander help was observed upon ad-
ministration of the immunodominant CTL epitope in
combination with the ovalbumin T helper peptide (Fig. 2
C), although the difference was not found to be statistically
significant from vaccination with the CTL epitope alone.
Bystander help can be beneficial for CTL induction as
shown by others (32). This might be due to cytokines pro-
duced by Ova-specific T helper cells during the priming
phase leading to increased numbers of CTL precursors. In
the effector phase after tumor challenge the Ova-specific T
helper cells will not be activated.
CTL induction in vivo has classically been reported to be
Figure 6. Cytotoxic T cells
isolated from protected mice rec-
ognize the immunodominant
MuLV gag-L peptide. CD81 T
cell bulk cultures were isolated
from spleen cells of a C57BL/6
mouse that was immunized with
the H11.1 T helper peptide and
survived RMA tumor challenge.
2H9 was a representative clone
isolated from this RMA-specific
bulk culture by limiting dilution.
(A) Cytotoxicity assay using
RMA cells and HeLa cells selec-
tively transfected with the
MHC class I Db molecule as tar-
get cells. HeLaDb cells were in-
cubated with the gag-L (CCL-
CLTVFL) peptide (1 mg/ml)
during the assay. (B) No reactiv-
ity of 2H9 CTL clone with the T helper peptide sequence. EL-4 cells (H-2b) were incubated with different synthetic peptides (1 mg/ml). gag-L–Db9 is
the dominant gag-L epitope CCLCLTVFL; gag-L–SIV9, another upstream gag-leader sequence reported to comprise a CTL epitope SIVLCCLCL (31).700 T Helper Cell Defense against MHC Class II Negative Tumors
T helper dependent (33), but synthetic peptide vaccination
studies using the minimal CTL epitope sequence were ei-
ther shown to be T helper independent (16) or dependent
(34, 35) in different virus systems. Here, we report induc-
tion of protective CTL-mediated immunity by vaccination
with a T helper epitope by itself or in combination with a
CTL epitope indicating T helper dependence for optimal
protection. The requirement for physical linkage between
CTL and the T helper peptide as shown for HIV (36) is not
essential since a single vaccination with a mixture of T
helper and CTL epitopes in IFA induces efficient protec-
tive immunity.
Recent experiments by Bennett et al. (37) indicate that
induction of CTL responses by cross-priming requires cog-
nate T cell help, involving presentation of both CTL and
helper epitopes on the same APC. We consider these find-
ings in line with our study. Local specific help appears to be
crucial for efficient CTL-mediated tumor control. This can
only be expected when APCs present tumor-derived anti-
genic fragments to tumor-specific T helper cells. This ex-
plains why nonrelated bystander (OVA-specific) help is far
less efficient. In conclusion, optimal virus or tumor vac-
cines should preferably contain both antigen-specific CTLs
and T helper epitopes.
Vaccination with the MuLV-env–gp70 T helper peptide
in IFA leads to activation of CD41 T cells that exhibit a
Th1 type cytokine production pattern as established in
vitro at the clonal level. The Th1 type appears to be cru-
cially related to the cellular (cytotoxic) response leading to
tumor cell destruction. The essential rules for peptide vac-
cination inducing the required T helper type are presently
not understood. In future experiments, we will purposely
direct the T helper type response using specific antibodies
and cytokines and monitor the effects on tumor protection.
Greenberg (5), in adoptive transfer experiments of FBL-
specific CD41 T cells, found macrophages to be a main ef-
fector population next to CTLs. We have performed adop-
tive transfer experiments with our specific CTL and Th
clones in RMA tumor-bearing nude mice (our unpub-
lished observations). We were able to control RMA tumor
growth by intravenous infusion of the gag-L–specific CTL
clone in combination with subcutaneous IL-2 or in combi-
nation with the T helper clone. In contrast, the T helper
clone by itself could only partially control tumor out-
growth in these T cell–deficient mice, possibly by activat-
ing macrophages into tumoricidal effector cells (5). There-
fore, we conclude that CTLs are important effector cells in
this system, but we do not exclude other effector mecha-
nisms operating in vivo. Macrophages and/or other profes-
sional APCs of the dendritic cell lineage are likely to play
an important role in the cross-presentation of tumor anti-
gens. Vaccination studies using vaccinia virus containing a
chimeric Friend MuLV env gene resulted in CD4- and
CD8-dependent protection against Friend virus–induced
erythroid proliferation (38). Miyazawa et al. (39) showed
protective effects of env-gp70 T helper peptide vaccination
against Friend virus, especially by a I-Eb/k–binding peptide.
Here, the mechanism was reported to be control of infec-
tion by induction of virus-neutralizing antibodies or direct
effects of the CD41 T cells. In our study, using an estab-
lished tumor cell line, peptide vaccination and CD8 deple-
tion studies strongly indicate a dominant role for Rauscher
MuLV-specific CTL.
We have explored the possibility of using the helper and
CTL epitope-containing synthetic peptides for therapeutic
use in mice bearing RMA tumors or when tumor cells
were administered at the same day of vaccination. Thus far,
using the IFA protocol, we were not able to control this
extremely aggressive tumor cell line in a therapeutic set up.
Apparently, the naive immune system cannot control this
rapidly dividing, established tumor cell line. Other ways of
efficient activation of the immune system, i.e., using pep-
tide-loaded dendritic cells (22), will be investigated in this
model.
Peptide vaccines are generally extremely potent in vivo,
but peptide administration can lead to either induction of
protective responses or (unwanted) induction of specific T
cell tolerance. This has been found for CTL epitopes in
both virus (40) and tumor models (41, 42). Peptide vacci-
nation with the LCMV CTL epitope can lead to induction
of immunity, but is dose and route dependent. For immu-
nization rather than tolerance induction, only a single dose
of peptide in a quite narrow window is required (40). In
the adenovirus tumor model, peptide-induced tolerization
is dose independent (41, 42). In the MuLV system in
which we use an identical peptide administration protocol,
both T helper and CTL peptide vaccination appear to lead
to activation rather than functional deletion of specific T
cells. Our study with an intraperitoneally growing tumor
shows that T helper peptide administration in IFA is pro-
tective across a wide dose of peptides of varying lengths.
However, T helper peptides can induce tolerance as shown
by the ovalbumin peptide (43), dependent on the mode of
peptide delivery. Our findings indicate that T helper pep-
tide vaccination with a single subcutaneous dose in IFA
leads to immunization rather than tolerization.
The use of T helper epitopes in vaccines can have poten-
tial advantages. First, T helper cells might play an important
role not only for optimal induction of CTL responses as re-
ported in this paper, but also for maintainance of CTL
memory as reported for LCMV (44, 45) and g-herpesvirus
(46). Secondly, the regulatory role of T helper cells allows
recruitment of several effector systems next to CTLs that
one can make use of to specifically attack tumor cells. Uti-
lization of specific cytokines, antibodies, or adjuvants al-
lows one to selectively tilt the response towards cells of the
Th1 or Th2 type. And thirdly, T helper peptides are usu-
ally more promiscuous in binding to MHC class II mole-
cules than CTL epitopes are for MHC class I. This opens
the possibility that T helper–based vaccines are less allele
dependent and thereby widely applicable. Inclusion of
CTL epitopes next to T helper epitopes in vaccines never-
theless seems unavoidable for optimal action. Finally, these
findings illustrate the importance of identification of tu-
mor-specific T helper epitopes, even if tumor cells lack
MHC class II expression.701 Ossendorp et al.
References
1. Ostrand-Rosenberg, S., A. Thakur, and V. Clements. 1990.
Rejection of mouse sarcoma cells after transfection of MHC
class II genes. J. Immunol. 144:4068–4071.
2. James, R., S. Edwards, K. Hui, P. Bassett, and F. Grosveld.
1991. The effect of class II gene transfection on the tumori-
genicity of the H-2k negative mouse leukemia cell line
K36.16.  Immunology. 72:213–218.
3. Chen, P., and H. Aanathaswamy. 1993. Rejection of K1735
murine melanoma in syngeneic hosts requires expression of
MHC class I antigens and either class II antigens or IL-2. J.
Immunol. 151:244–255.
4. Yoshimura, A., H. Shiku, and E. Nakayama. 1993. Rejection
of an IA1 variant line of FBL-3 leukemia by cytotoxic T
lymphocytes with CD41 and CD42CD82 T cell receptor-ab
phenotypes generated in CD8-depleted C57BL/6 mice. J.
Immunol. 150:4900–4910.
5. Greenberg, P.D. 1991. Adoptive T cell therapy of tumors:
mechanisms operative in the recognition and elimination of
tumor cells. Adv. Immunol. 49:281–355.
6. Klarnet, J.P., D.E. Kern, K. Okunu, C. Holt, F. Lilly, and
P.D. Greenberg. 1989. FBL-reactive CD8 cytotoxic and
CD4 helper T cells recognize distinct Friend murine leuke-
mia virus–encoded antigens. J. Exp. Med. 169:457–467.
7. Hu, J., W. Kindsvogel, S. Busby, M.C. Bailey, Y. Shi, and
P.D. Greenberg. 1993. An evaluation of the potential to use
tumor-associated antigens as targets for antitumor T cell ther-
apy using transgenic mice expressing a retroviral tumor anti-
gen in normal lymphoid tissues. J. Exp. Med. 177:1681–1690.
8. Lilly, F., E.A. Boyse, and L.J. Old. 1964. Genetic basis of sus-
ceptibility to viral leukemogenesis. Lancet. ii:1207–1209.
9. Vasmel, W.L.J., M. Zijlstra, T. Radaszkiewicz, C.J.M. Leu-
pers, R.E.Y. De Goede, and C.J.M. Melief. 1988. Major his-
tocompatibility class II regulated immunity to murine leukemia
virus protects against early T- but not late B-cell lymphomas.
J. Virol. 62:3156–3166.
10. Chesebro, B., B. Miyazawa, and W.J. Britt. 1990. Host
genetic control of spontaneous and induced immunity to
Friend murine retrovirus infection. Annu. Rev. Immunol. 8:
477–499.
11. Iwashiro, M., T. Kondo, T. Shimizu, H. Yamagishi, K. Ta-
kahashi, Y. Matsubayashi, T. Masuda, A. Otaka, N. Fujii, A.
Ishimoto, et al. 1993. Multiplicity of virus-encoded helper
T-cell epitopes expressed on FBL-3 tumor cells. J. Virol. 67:
4533–4542.
12. Vasmel, W.L.E., E.J.A.M. Sijts, C.J.M. Leupers, E.A. Mat-
thews, and C.J.M. Melief. 1989. Primary virus–induced lym-
phomas evade T cell immunity by failure to express viral an-
tigens. J. Exp. Med. 169:1233–1254.
13. Plata, F., P. Langlade-Demoyen, J.P. Abastado, T. Berbar,
and P. Kourilsky. 1987. Retrovirus antigens recognized by
cytotoxic T lymphocytes activate tumor rejection in vivo.
Cell. 48:231–240.
14. Sijts, A.J.A.M., M.L. De Bruijn, M.E. Ressing, J.D. Nieland,
E.A.M. Mengedé, C.J. Boog, F. Ossendorp, W.M. Kast, and
C.J.M. Melief. 1994. Identification of an H-2 Kb–presented
Moloney murine leukemia virus cytotoxic T lymphocyte
epitope that displays enhanced recognition in H-2 Db mutant
bm13 mice. J. Virol. 68:6038–6046.
15. Chen, W., H. Qin, B. Chesebro, and M.A. Cheever. 1996.
Identification of a gag-encoded cytotoxic T lymphocyte
epitope from FBL-3 leukemia shared by Friend, Moloney,
and Rauscher murine leukemia virus–induced tumors. J. Vi-
rol. 70:7773–7782.
16. Kast, W.M., L. Roux, J. Curren, H.J.J. Blom, A.C. Voor-
douw, R.H. Meloen, D. Kolakofski, and C.J.M. Melief.
1991. Protection against lethal Sendai virus infection by in
vivo priming of virus-specific cytotoxic T lymphocytes with
an unbound peptide. Proc. Natl. Acad. Sci. USA. 88:2283–
2287.
17. Schulz, M., R.M. Zinkernagel, and H. Hengartner. 1991.
Peptide-induced antiviral protection by cytotoxic T cells.
Proc. Natl. Acad. Sci. USA. 88:991–993.
18. Feltkamp, M.C.W., H.L. Smits, M.P.M. Vierboom, R.P.
Minnaar, B.M. De Jongh, J.W. Drijfhout, J. Ter Schegget,
C.J.M. Melief, and W.M. Kast. 1993. Vaccination with a cy-
totoxic T lymphocyte epitope-containing peptide protects
against a tumor induced by human Papillomavirus type 16-
transformed cells. Eur. J. Immunol. 23:2242–2249.
19. Schild, H., M. Norda, K. Deres, K. Falk, O. Rötschke, K.-H.
Wiesmüller, G. Jung, and H.-G. Rammensee. 1991. Fine
specificity of cytotoxic T lymphocytes primed in vivo either
with virus or synthetic lipopeptide vaccine or primed in vitro
with peptide. J. Exp. Med. 174:1665–1668.
20. Minev, B.R., B.J. McFarland, P.J. Spiess, S.A. Rosenberg,
and N.P. Restifo. 1994. Insertion signal sequence fused to
minimal peptides elicits specific CD81 T-cell responses and
prolongs survival of thymoma-bearing mice. Cancer Res. 54:
4155–4161.
21. Mandelboim, O., E. Vadai, M. Fridkin, A. Katz-Hillel, M.
Feldman, G. Berke, and L. Eisenbach. 1995. Regression of
established murine carcinoma metastases following vaccina-
tion with tumour-associated antigen peptides. Nat. Med. 1:
1179–1183.
22. Mayordomo, J.I., T. Zorina, W.J. Storkus, L. Zitvogel, C.
Celluzzi, L.D. Falo, C.J.M. Melief, S.T. Ildstad, W.M. Kast,
A.B. Deleo, and M.T. Lotze. 1995. Bone marrow–derived
We wish to thank Drs. R. Offringa, F. Koning, and T. Ottenhoff for critically reading the manuscript, Dr.
J.W. Drijfhout for synthesis of peptides, Dr. R. Schipper for statistical analysis, and G. Schijff (TNO-PG) for
excellent biotechnical assistance.
This study was financed by the Netherlands Cancer Foundation grants 93-560 and 97-1451.
Address correspondence to F. Ossendorp, Department of Immunohematology and Bloodbank, University
Hospital Leiden, Bldg. 1, E3-Q, PO Box 9600, 2300 RC Leiden, The Netherlands. Phone: 31-71-
5263800; Fax: 31-71-5216751; E-mail: ossendorp@rullf2.medfac.leidenuniv.nl
Received for publication 1 August 1997 and in revised form 21 November 1997.702 T Helper Cell Defense against MHC Class II Negative Tumors
dendritic cells pulsed with synthetic tumour peptides elicit pro-
tective and therapeutic antitumour immunity. Nat. Med. 1:
1297–1302.
23. Sijts, A.J.A.M., F. Ossendorp, E.A.M. Mengedé, P.J. van den
Elsen, and C.J.M. Melief. 1994. Immunodominant mink cell
focus-inducing murine leukemia virus (MuLV)-encoded CTL
epitope, identified by its MHC class I binding motif, explains
MuLV-type specificity of MCF-directed cytotoxic T lym-
phocytes. J. Immunol. 152:106–116.
24. Ljunggren, H.-G., and K. Kärre. 1985. Host resistance di-
rected selectively against H-2 deficient lymphoma variants. J.
Exp. Med. 162:1745–1759.
25. Stukart, M.J., A. Vos, and C.J.M. Melief. 1981. Cytotoxic T
cell response against lymphoblasts infected with Moloney
(Abelson) murine leukemia virus. Methodological aspects and
H-2 requirements. Eur. J. Immunol. 11:251–257.
26. Gausepohl, H., M. Kraft, C. Boulin, and R.W. Frank. 1990.
Automated multiple peptide synthesis with BOP activation.
In Proc. of the 11th American Peptide Symposium. J.E. Rivier
and G.R. Marshall, editors. ESCOM, Leiden. 1003–1004.
27. Shimonkevitz, R., S. Colon, J.W. Kappler, P. Marrack, and
H.M. Grey. 1984. Antigen recognition by H-2–restricted
T cells. II. A tryptic ovalbumin peptide that substitutes for
processed antigen. J. Immunol. 133:2067–2074.
28. Bouaboula, M., P. Legoux, B. Pességué, B. Delpech, X. Du-
mont, M. Piechaczyk, P. Casellas, and D. Shire. 1992. Quan-
titation of cytokine gene expression using a polymerase chain
reaction method involving co-amplification with an internal
multi-specific control. J. Biol. Chem. 267:21830–21838.
29. Ossendorp, F., M. Eggers, A. Neisig, T. Ruppert, M. Groet-
trup, A. Sijts, E. Mengedé, P. Kloetzel, J. Neefjes, U. Koszi-
nowski, and C. Melief. 1996. A single residue exchange
within a viral CTL epitope alters proteasome-mediated deg-
radation resulting in lack of antigen presentation. Immunity. 5:
115–124.
30. Shimizu, T., H. Uenishi, Y. Teramura, M. Iwashiro, K.
Kuribayashi, H. Tamamura, N. Fujii, and H. Yamagishi.
1994. Fine specificity of a virus-encoded helper T-cell
epitope expressed on FBL-3 tumor cells. J. Virol. 68:7704–
7708.
31. Kondo, T., H. Uenishi, T. Shimizu, T. Hirama, M. Iwashiro,
K. Kuribayashi, H. Tamamura, N. Fujii, R. Fujisawa, and H.
Yamagishi. 1995. A single retroviral gag precursor signal pep-
tide recognized by FBL-3 tumor-specific cytotoxic T lym-
phocytes. J. Virol. 69:6735–6741.
32. Alexander, J., J. Sidney, S. Southwood, J. Ruppert, C. Ose-
roff, A. Maewal, K. Snoke, H.M. Serra, R.T. Kubo, A. Sette,
and H. Grey. 1994. Development of high potency universal
DR-restricted helper epitopes by modification of high affin-
ity DR-blocking peptides. Immunity. 1:751–761.
33. Keene, J.A., and J. Forman. 1982. Helper activity is required
for the induction of cytotoxic T lymphocytes. J. Exp. Med.
155:768–782.
34. Gao, X-M., B. Zheng, F.Y. Liew, S. Brett, and J. Tite. 1991.
Priming of influenza virus–specific cytotoxic T lymphocytes in
vivo by short synthetic peptides. J. Immunol. 147:3168–3173.
35. Fayolle, C., E. Deriaud, and C. Leclerc. 1991. In vivo induc-
tion of cytotoxic T cell response by a free synthetic peptide
requires CD41 T cell help. J. Immunol. 147:4069–4073.
36. Shirai, M., C.D. Pendleton, J. Ahlers, T. Takeshita, M. New-
man, and J.A. Berzofsky. 1994. Helper-cytotoxic T lym-
phocyte (CTL) determinant linkage required for priming of
HIV CD81 CTL in vivo with peptide vaccine constructs. J.
Immunol. 152:529–556.
37. Bennett, S.R.M., F.R. Carbone, F. Karamalis, J.F.A.P.
Miller, and W.R. Heath. 1997. Induction of a CD81 cyto-
toxic T lymphocyte response by cross-priming requires cog-
nate CD41 T cell help. J. Exp. Med. 186:65–70.
38. Hasenkrug, K.J., D.M. Brooks, J. Nishio, and B. Chesebro.
1996. Differing T-cell requirements for recombinant retrovi-
rus vaccines. J. Virol. 70:368–372.
39. Miyazawa, M., R. Fujisawa, C. Ishihara, Y.A. Takei, T.
Shimizu, H. Uenishi, H. Yamagishi, and K. Kuribayashi.
1995. Immunization with a single T helper cell epitope abro-
gates Friend virus–induced early erythroid proliferation and
prevents late leukemia development. J. Immunol. 155:748–758.
40. Aichele, P., K. Brduscha-Riem, R.M. Zinkernagel, H. Hen-
gartner, and H. Pircher. 1995. T cell priming versus T cell
tolerance induced by synthetic peptides. J. Exp. Med. 182:
261–266.
41. Toes, R.E.M., R.J.J. Blom, R. Offringa, W.M. Kast, and
C.J.M. Melief. 1996. Functional deletion of tumor-specific
cytotoxic T lymphocytes induced by peptide immunization
can lead to the inability to reject tumors. J. Immunol. 156:
3911–3918.
42. Toes, R.E.M., R. Offringa, R.J.J. Blom, C.J.M. Melief, and
W.M. Kast. 1996. Peptide vaccination can lead to enhanced
tumor outgrowth through specific T-cell tolerance induc-
tion.  Proc. Natl. Acad. Sci. USA. 93:7855–7860.
43. Kearney, E.R., K.A. Pape, D.Y. Loh, and M.K. Jenkins.
1994. Visualization of peptide induced T cell immunity and
peripheral tolerance induction in vivo. Immunity. 1:327–339.
44. Matloubian, M., R.J. Concepcion, and R. Ahmed. 1994.
CD41 T cells are required to sustain CD81 cytotoxic T-cell
responses during chronic viral infection. J. Virol. 68:8056–
8063.
45. Von Herrath, M.G., M. Yokoyama, J. Dockter, M.B.A. Old-
stone, and J.L. Whitton. 1996. CD4-deficient mice have re-
duced levels of memory cytotoxic T lymphocytes after im-
munization and show diminished resistance to subsequent
virus challenge. J. Virol. 70:1072–1079.
46. Cardin, R.D., J.W. Brooks, S.R. Sarawar, and P.C. Doherty.
1996. Progressive loss of CD81 T cell-mediated control of a
g-herpesvirus in the absence of CD41 T cells. J. Exp. Med.
184:863–871.